Toll Free: 1-888-928-9744
Published: Apr, 2014 | Pages:
46 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Grifols, S.A. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Grifols, S.A. - Product Pipeline Review - 2014', provides an overview of the Grifols, S.A.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Grifols, S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Grifols, S.A. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Grifols, S.A.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Grifols, S.A.'s pipeline products Reasons to buy - Evaluate Grifols, S.A.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Grifols, S.A. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Grifols, S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Grifols, S.A. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Grifols, S.A. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Grifols, S.A. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Grifols, S.A. Snapshot 5 Grifols, S.A. Overview 5 Key Information 5 Key Facts 5 Grifols, S.A. - Research and Development Overview 6 Key Therapeutic Areas 6 Grifols, S.A. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Grifols, S.A. - Pipeline Products Glance 11 Grifols, S.A. - Late Stage Pipeline Products 11 Phase III Products/Combination Treatment Modalities 11 Grifols, S.A. - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 Grifols, S.A. - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Grifols, S.A. - Drug Profiles 15 ARD-3150 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 immune globulin (human) 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 albumin (human) 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Human Plasmin 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Recombinant A1PI 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 ARD-3100 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 fibrinogen 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Human Coagulation Factor-VIII 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Recombinant Plasmin 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Grifols, S.A. - Pipeline Analysis 28 Grifols, S.A. - Pipeline Products by Target 28 Grifols, S.A. - Pipeline Products by Route of Administration 30 Grifols, S.A. - Pipeline Products by Molecule Type 31 Grifols, S.A. - Pipeline Products by Mechanism of Action 32 Grifols, S.A. - Recent Pipeline Updates 34 Grifols, S.A. - Dormant Projects 40 Grifols, S.A. - Locations And Subsidiaries 41 Head Office 41 Other Locations & Subsidiaries 41 Appendix 45 Methodology 45 Coverage 45 Secondary Research 45 Primary Research 45 Expert Panel Validation 45 Contact Us 46 Disclaimer 46
List of Tables Grifols, S.A., Key Information 5 Grifols, S.A., Key Facts 5 Grifols, S.A. - Pipeline by Indication, 2014 8 Grifols, S.A. - Pipeline by Stage of Development, 2014 9 Grifols, S.A. - Monotherapy Products in Pipeline, 2014 10 Grifols, S.A. - Phase III, 2014 11 Grifols, S.A. - Phase II, 2014 12 Grifols, S.A. - Phase I, 2014 13 Grifols, S.A. - Preclinical, 2014 14 Grifols, S.A. - Pipeline by Target, 2014 29 Grifols, S.A. - Pipeline by Route of Administration, 2014 30 Grifols, S.A. - Pipeline by Molecule Type, 2014 31 Grifols, S.A. - Pipeline Products by Mechanism of Action, 2014 33 Grifols, S.A. - Recent Pipeline Updates, 2014 34 Grifols, S.A. - Dormant Developmental Projects,2014 40 Grifols, S.A., Other Locations 41 Grifols, S.A., Subsidiaries 42
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.